Tagged with Kyowa Kirin

Japan Some of the biggest stories coming out of Japanese pharma, including Takeda’s USD 2.2 billion Alzheimer’s deal with AC Immune and its plans to restructure; the continuing probe into deaths linked to a Kobayashi Pharmaceutical supplement; Kyowa Kirin’s acquisition of Orchard Therapeutics, and Shionogi’s buy up of Maze Therapeutics’ Pompe…

Saudi Arabia While international pharma has long been present in Saudi Arabia, the ambitious goals outlined in the country’s Vision 2030 economic transformation plan have encouraged companies to reinforce their commitment to the Kingdom. In recent PharmaBoardroom interviews, Saudi pharma country managers reveal their priorities and concerns.   Saudi Arabia holds immense…

Saudi Arabia Mohamed Abu Shawish of Japanese rare disease specialist Kyowa Kirin outlines how, by focusing on initiatives like genetic testing programs and facilitating treatment delivery to remote areas, the company ensures that rare disease patients in Saudi Arabia receive timely diagnoses and access to essential treatments. He also explains how the…

UAE Globally, while there is broad stakeholder alignment on topics like clinical trials and innovation, there is real divergence in approaches to pharmacoeconomics and health technology assessment (HTA). This is perhaps in part due to the differences between systems like those in Europe where these functions are state mandates and those,…

UAE Erstwhile general manager for the GCC countries at Japanese-headquartered rare disease specialist Kyowa Kirin, earlier this year Myriam Hakim was appointed as the firm’s regional nephrology franchise head for the entire EMEA region. Here, Hakim discusses some of the key challenges she navigated the GCC grouping through over the past…

UAE Mohamed Abu Shawish discusses some of the core challenges facing rare disease patients in the GCC region and how Kyowa Kirin is engaging in multi-stakeholder partnerships across the healthcare sector to help solve them.   It is important that if a patient is diagnosed, the treatment is always readily available,…

Japan Japan is known for its cutting-edge technology, innovative products, and world-class healthcare system. The pharmaceutical industry in Japan is no exception, with many leading companies making significant contributions to global health and wellness. Read on for a rundown of the top 10 Japanese pharmaceutical companies (based on market capitalisation in…

Spain Kyowa Kirin’s head of the South Europe cluster, Norberto Villarrasa, explains the Japanese company’s presence in Spain, its focus on rare diseases and onco-haematology, and comments on the challenges around access to rare disease treatments. In addition, the executive provides the company’s view on the potential and advantages of risk-sharing…

Japan The latest healthcare and pharma news from Japan, including Shionogi’s COVID-19 pill, the Japanese parliament’s green light for emergency approvals of drugs and vaccines and Hitachi’s partnership with Invivoscribe.   Shionogi’s COVID-19 pill  (Reuters) The future of Shionogi & Co Ltd’s experimental treatment, S-217622, is still uncertain. The company recently…

Japan Japanese firm Kirin, part of the Mitsubishi Group and best known for its brewing operations, has pledged to invest JPY 100 billion (USD 870 million) into its healthcare/pharma operations amid a slowdown in the Japanese beer market.   Beer Today, Gone Tomorrow Japan’s rapidly ageing population and the effects of…

Italy Claudia Coscia outlines how the geographic and portfolio transformation of Kyowa Kirin has played out in Italy in recent years. Coscia also touches on access challenges for rare disease therapies in the Italian pharma market, rising levels of rare disease awareness, and the digitalisation status of the country’s healthcare system. …

Japan A roundup of the latest news from Japanese pharma, including Kirin’s USD 870 million investment in its healthcare and pharmaceuticals businesses over the next three years, Sanofi’s world-first approval for its Niemann-Pick types A/B and B medicine in Japan, and the prospect of domestically developed COVID-19 vaccines being rolled out…